BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering

benzinga.com/m-a/25/06/46142142/biocryst-just-ditched-its-europe-business-heres-why-investors-are-cheering

BioCryst Pharmaceuticals (NASDAQ:BCRX) agrees to sell its European Orladeyo (berotralstat) business to Neopharmed Gentili for up to $264 million.
Orladeyo (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and…

This story appeared on benzinga.com, 2025-06-27 14:41:23.
The Entire Business World on a Single Page. Free to Use →